Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioXcel TherapeuticsBTAIQ -34.14% EV-to-OCF is -1.85 as of Sep. 09, 2026. The stock has 2 warning signs investors should review. Among 1,007 Drug Manufacturers companies, BioXcel Therapeutics ranks better than 73.49% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, BioXcel Therapeutics's Enterprise Value is $93.92 Mil.
BioXcel Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $-50.90 Mil. Therefore, BioXcel Therapeutics's EV-to-OCF for today is -1.85.
The historical rank and industry rank for BioXcel Therapeutics's EV-to-OCF or its related term are showing as below:
BTAIQ'
s EV-to-OCF Range Over the Past 10 Years
Min: -6.13 Med: -1.44 Max: -0.27
Current: -1.85
During the past 10 years, the highest EV-to-OCF of BioXcel Therapeutics was -0.27. The lowest was -6.13. And the median was -1.44.
BTAIQ's EV-to-OCF is ranked better than 73.49% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 10.53
vs BTAIQ: -1.85
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioXcel Therapeutics's PE Ratio (TTM) for today is calculated as:
BioXcel Therapeutics's share price for today is $0.04292.
BioXcel Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.772.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BioXcel Therapeutics EV-to-OCF Related Terms
BioXcel Therapeutics EV-to-OCF Historical Data
* Premium members only.
The historical data trend for BioXcel Therapeutics's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BioXcel Therapeutics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioXcel Therapeutics EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioXcel Therapeutics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where BioXcel Therapeutics's EV-to-OCF falls into.
BioXcel Therapeutics's current Enterprise Value is $93.92 Mil.
BioXcel Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-50.90 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioXcel Therapeutics (BTAIQ) has a EV-to-OCF of -1.85 as of Sep. 09, 2026. According to the industry distribution chart, BioXcel Therapeutics ranks #267 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 26.5%.
Is BioXcel Therapeutics' EV-to-OCF too high?
BioXcel Therapeutics' current EV-to-OCF is -1.85. Based on the distribution chart, BioXcel Therapeutics ranks #267 out of 1007 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does BioXcel Therapeutics' EV-to-OCF compare to YCBD and APUS?
According to the Drug Manufacturers industry distribution chart, BioXcel Therapeutics ranks #267 out of 1007 companies for EV-to-OCF. This puts BioXcel Therapeutics in the upper half of its industry. The industry median EV-to-OCF is 10.53. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.53, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioXcel Therapeutics's current EV-to-OCF is -1.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioXcel Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, BioXcel Therapeutics (BTAIQ) is currently considered Possible Value Trap. The stock's GF Value™ is $0.53, compared to a current price of $0.04 — trading 91.9% below its estimated fair value. The current EV-to-OCF is -1.85. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For BioXcel Therapeutics (BTAIQ), the current EV-to-OCF is -1.85 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are-BXCL501, being evaluated as a potential treatment for agitation associated with multiple neurological disorders and BXCL701, an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer and other solid and liquid tumors. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BTAIQ has been successfully added to your 
